{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:04:29Z","timestamp":1759777469470,"version":"3.41.2"},"reference-count":48,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ci\u00eanc. sa\u00fade coletiva"],"abstract":"<jats:p>Resumo No Sistema \u00danico de Sa\u00fade os medicamentos do grupo 1 do Componente Especializado da Assist\u00eancia Farmac\u00eautica (CEAF) s\u00e3o financiados pela Uni\u00e3o e adquiridos de forma centralizada (grupo 1A) ou por cada Unidade Federativa (UF) (grupo 1B). Diferentemente de outros pa\u00edses onde se negocia um pre\u00e7o fixo a ser praticado no sistema p\u00fablico, no Brasil as aquisi\u00e7\u00f5es s\u00e3o realizadas por licita\u00e7\u00e3o, o que pode levar a diferentes pre\u00e7os. Para permitir a compara\u00e7\u00e3o de pre\u00e7os, foi pactuada a obrigatoriedade de registro das aquisi\u00e7\u00f5es p\u00fablicas no Banco de Pre\u00e7os em Sa\u00fade (BPS). O estudo teve como objetivo analisar a variabilidade dos pre\u00e7os de medicamentos do grupo 1B adquiridos pelas UF do Brasil em 2021. Foram obtidas as aquisi\u00e7\u00f5es de medicamentos do grupo 1B realizadas pelas Secretarias de Estado das 27 UF por consulta ao BPS excluindo-se os medicamentos sem pre\u00e7o de ressarcimento estabelecido em dezembro\/2021. Foi obtido do Sistema de Informa\u00e7\u00f5es Ambulatoriais o ressarcimento para cada UF. Verificou-se grande variabilidade dos pre\u00e7os de aquisi\u00e7\u00e3o para cada medicamento entre as UF e dentro da mesma UF. O estudo demonstrou potencial iniquidade de acesso ao CEAF, privilegiando com menores pre\u00e7os UF mais favorecidas (maior popula\u00e7\u00e3o e riqueza).<\/jats:p>","DOI":"10.1590\/1413-81232024291.18142022","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T20:44:27Z","timestamp":1704746667000},"source":"Crossref","is-referenced-by-count":3,"title":["Variabilidade de pre\u00e7os de aquisi\u00e7\u00e3o de medicamentos do grupo 1B do Componente Especializado da Assist\u00eancia Farmac\u00eautica"],"prefix":"10.1590","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-7359","authenticated-orcid":false,"given":"Paula","family":"Rossignoli","sequence":"first","affiliation":[{"name":"Universidade Federal do Paran\u00e1 (UFPR),  Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"UFPR,  Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[{"name":"Universidade do Porto,  Portugal"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"year":"2014","series-title":"Minist\u00e9rio da Sa\u00fade (MS). Componente especializado da assist\u00eancia farmac\u00eautica: Inova\u00e7\u00e3o para a garantia do acesso a medicamentos no SUS","key":"ref1"},{"issue":"8","key":"ref2","article-title":"The incorporation of nusinersen by the Brazilian Unified National Health System critical thoughts on the institutionalization of health technology assessment in Brazil","volume":"35","author":"Caetano R","year":"2019","journal-title":"Cad Saude Publica"},{"series-title":"Evolu\u00e7\u00e3o do gasto com medicamentos do sistema \u00fanico de sa\u00fade no per\u00edodo de 2010 a 2016 [Internet]","author":"Vieira FS","key":"ref3"},{"issue":"3","key":"ref4","first-page":"245","article-title":"Use of pharmaceutical care programs records of the Outpatient Information System for the assessment of patient's medication use and adherence","volume":"21","author":"Soares C","year":"2013","journal-title":"Cien Saude Colet"},{"issue":"4","key":"ref5","first-page":"1241","article-title":"Profile of spending on the treatment of rheumatoid arthritis for patients of the Unified Health System in the state of Minas Gerais - 2008-2013","volume":"23","author":"Silva GDD","year":"2018","journal-title":"Cien Saude Colet"},{"issue":"11","key":"ref6","first-page":"5481","article-title":"Challenges in the management of high-priced drugs in the SUS evaluation of Pharmaceutical Policy in Sao Paulo, Brazil","volume":"26","author":"Fatel KO","year":"2021","journal-title":"Cien Saude Colet"},{"issue":"11","key":"ref7","first-page":"5499","article-title":"Access to high-priced medicines inequalities in the organization and the results among Brazilian states","volume":"26","author":"Rover MRM","year":"2021","journal-title":"Cien Saude Colet"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17512433.2021.1865799","article-title":"Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications","volume":"14","author":"Barbosa WB","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"ref9","first-page":"2471","article-title":"Incorporation of medicines in the Unified Health System (SUS) comparison between oncology and the specialized component of pharmaceutical care","volume":"27","author":"Capucho HC","year":"2022","journal-title":"Cien Saude Colet"},{"issue":"3","key":"ref10","article-title":"Assessment of the economic savings and advantages of Productive Development Partnerships","volume":"37","author":"Albareda A","year":"2021","journal-title":"Cad Saude Publica"},{"year":"2017","series-title":"Portaria de Consolida\u00e7\u00e3o n\u00ba 6, de 28 de setembro de 2017. Consolida\u00e7\u00e3o das normas sobre o financiamento e a transfer\u00eancia dos recursos federais para as a\u00e7\u00f5es e os servi\u00e7os de sa\u00fade do Sistema \u00danico de Sa\u00fade","key":"ref11"},{"series-title":"Relat\u00f3rio de gest\u00e3o 2021 [Internet]","key":"ref12"},{"year":"1993","series-title":"Lei n\u00ba 8.666, de 21 de junho de 1993. Regulamenta o art. 37, inciso XXI, da Constitui\u00e7\u00e3o Federal, institui normas para licita\u00e7\u00f5es e contratos da Administra\u00e7\u00e3o P\u00fablica e d\u00e1 outras provid\u00eancias","key":"ref13"},{"year":"1999","series-title":"Lei n\u00ba 9.787, de 10 de Fevereiro de 1999. Altera a Lei n\u00ba 6.360, de 23 de setembro de 1976, que disp\u00f5e sobre a vigil\u00e2ncia sanit\u00e1ria, estabelece o medicamento gen\u00e9rico, disp\u00f5e sobre a utiliza\u00e7\u00e3o de nomes gen\u00e9ricos em produtos farmac\u00eauticos e d\u00e1 outras provid\u00eancias","key":"ref14"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046917","article-title":"Determinants of drug prices a systematic review of comparison studies","volume":"11","author":"Janssen Daalen JM","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1590\/S0034-76122010000600007","article-title":"Fatores determinantes na varia\u00e7\u00e3o dos pre\u00e7os dos produtos contratados por preg\u00e3o eletr\u00f4nico","volume":"44","author":"Faria ER","year":"2010","journal-title":"Rev Admin Publica"},{"issue":"1","key":"ref17","first-page":"769","article-title":"Regula\u00e7\u00e3o, precifica\u00e7\u00e3o e incorpora\u00e7\u00e3o de medicamentos no Brasil","volume":"13","author":"Ivama-Brummell AM","year":"2022","journal-title":"Rev Bras Farm Hosp Serv Saude"},{"issue":"4","key":"ref18","first-page":"1313","article-title":"Specialized Pharmaceutical Services Component federative pact for ensuring the comprehensiveness of drug treatment in the Unified Health System (SUS)","volume":"21","author":"Alexandre RF","year":"2016","journal-title":"Cien Saude Colet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1590\/S0034-8910.2015049005779","article-title":"Problems in the regulatory policy of the drug market","volume":"49","author":"Miziara NM","year":"2015","journal-title":"Rev Saude Publica"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1590\/S1020-49892007000700006","article-title":"Retail prices of essential drugs in Brazil an international comparison","volume":"22","author":"Nobrega OT","year":"2007","journal-title":"Rev Panam Salud Publica"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.30968\/rbfhss.2022.132.0804","article-title":"The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK combining innovation and access","volume":"13","author":"Ivama-Brummell AM","year":"2022","journal-title":"Rev Bras Farm Hosp Serv Saude"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.30968\/rbfhss.2022.131.0639","article-title":"Pharmaceutical regulation and policies in Austria","volume":"13","author":"Vogler S","year":"2022","journal-title":"Rev Bras Farm Hosp Serv Saude"},{"issue":"3","key":"ref23","first-page":"861","article-title":"Avalia\u00e7\u00e3o de Tecnologias de Sa\u00fade em Portugal pol\u00edticas de sa\u00fade, metodologias e desafios emergentes","volume":"13","author":"Caldeira S","year":"2022","journal-title":"RBFHSS"},{"series-title":"Guia de Governan\u00e7a e Gest\u00e3o em Sa\u00fade: Aplic\u00e1vel a Secretarias e Conselhos de Sa\u00fade [Internet]","key":"ref24"},{"series-title":"Banco de Pre\u00e7os Em Sa\u00fade - BPS [Internet]","key":"ref25"},{"series-title":"Diretrizes Metodol\u00f3gicas: elabora\u00e7\u00e3o de Pareceres T\u00e9cnico-Cient\u00edficos [Internet]","key":"ref26"},{"issue":"7","key":"ref27","first-page":"1223","article-title":"Guidelines for budget impact analysis of health technologies in Brazil","volume":"28","author":"Ferreira-Da-Silva AL","year":"2012","journal-title":"Cad Saude Publica"},{"series-title":"Rela\u00e7\u00e3o Nacional de Medicamentos Essenciais 2022 [Internet]","key":"ref28"},{"year":"2020","series-title":"Resolu\u00e7\u00e3o n\u00ba 5, de 21 de dezembro de 2020. Divulga o novo Coeficiente de Adequa\u00e7\u00e3o de Pre\u00e7os (CAP)","key":"ref29"},{"series-title":"Rem\u00e9dio a Pre\u00e7o Justo [Internet]","key":"ref30"},{"issue":"1","key":"ref31","first-page":"679","article-title":"Medicines pricing and reimbursement innovation, competitiveness, and access","volume":"13","author":"Ivama-Brummell AM","year":"2022","journal-title":"RBFHSS"},{"issue":"3","key":"ref32","first-page":"14","article-title":"Experi\u00eancias de regula\u00e7\u00e3o de pre\u00e7os de medicamentos em pa\u00edses selecionados li\u00e7\u00f5es para o Brasil","volume":"9","author":"Souza CMA","year":"2021","journal-title":"Vigil Sanit Debate"},{"series-title":"Relat\u00f3rio de Avalia\u00e7\u00e3o: Componente Especializado da Assist\u00eancia Farmac\u00eautica (CEAF) [Internet]","key":"ref33"},{"issue":"1","key":"ref34","first-page":"37","article-title":"A descentraliza\u00e7\u00e3o do Componente Especializado da Assist\u00eancia Farmac\u00eautica na 15\u00aa regi\u00e3o de sa\u00fade do estado do Cear\u00e1","volume":"6","author":"Silva AA","year":"2015","journal-title":"RBFHSS"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1744-8603-8-6","article-title":"Is the Brazilian pharmaceutical policy ensuring population access to essential medicines","volume":"8","author":"Bertoldi AD","year":"2012","journal-title":"Global Health"},{"issue":"6","key":"ref36","article-title":"Prevalence rates and inequalities in access to medicines by users of the Brazilian Unified National Health System in 2013 and 2019","volume":"38","author":"Boing AC","year":"2022","journal-title":"Cad Saude Publica"},{"series-title":"Modelos de Organiza\u00e7\u00e3o da Assist\u00eancia Farmac\u00eautica na Aten\u00e7\u00e3o Ambulatorial: Uma An\u00e1lise Comparada [Internet]","key":"ref37"},{"issue":"6","key":"ref38","first-page":"72","article-title":"Pesquisa de Pre\u00e7os na Aquisi\u00e7\u00e3o P\u00fablica de Medicamentos","volume":"1","author":"Souza HO","year":"2020","journal-title":"Cad Esc Paul Contas Publicas"},{"issue":"11","key":"ref39","first-page":"5463","article-title":"Comparison between maximum consumer prices for medicines and prices practiced on the internet in Brazil misalignments and regulatory distortions","volume":"26","author":"Souza CMA","year":"2021","journal-title":"Cien Saude Colet"},{"series-title":"Ac\u00f3rd\u00e3o 527\/2020 [Internet]","key":"ref40"},{"issue":"5","key":"ref41","article-title":"The British National Health Service a history of reforms, 1990-2002","volume":"37","author":"Amadeo J","year":"2021","journal-title":"Cad Saude Publica"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"814","DOI":"10.30968\/rbfhss.2022.132.0814","article-title":"Italy - a study case of medicines pricing and reimbursement","volume":"13","author":"Melo VA","year":"2022","journal-title":"Rev Bras Farm Hosp Serv Saude"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40545-019-0183-0","article-title":"Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science","volume":"12","author":"Santos MAB","year":"2019","journal-title":"J Pharm Policy Pract"},{"issue":"8","key":"ref44","first-page":"2527","article-title":"Public procurement of hepatitis C medicines in Brazil from 2005 to 2015","volume":"22","author":"Chaves GC","year":"2017","journal-title":"Cien Saude Colet"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"010314","DOI":"10.7189\/jogh.10.010314","article-title":"Collective pharmaceutical procurement in China may have unintended consequences in supply and pricing","volume":"10","author":"Jiang S","year":"2020","journal-title":"J Glob Health"},{"series-title":"Or\u00e7amento tem\u00e1tico de acesso a medicamentos: an\u00e1lise de 10 anos de recursos federais destinados \u00e0 assist\u00eancia farmac\u00eautica [Internet]","author":"Silva LPA","key":"ref46"},{"series-title":"Infogr\u00e1ficos. Informativo do Instituto Neg\u00f3cios P\u00fablicos. Compras P\u00fablicas Edi\u00e7\u00e3o 2014 [Internet]","key":"ref47"},{"year":"2021","series-title":"Estados reclamam de atraso na entrega de rem\u00e9dios de alto custo pelo Minist\u00e9rio da Sa\u00fade [Internet]","author":"Cancian N","key":"ref48"}],"container-title":["Ci\u00eancia &amp; Sa\u00fade Coletiva"],"original-title":["Variability in Drug Procurement within Group 1B of the Pharmaceutical Specialized Scheme in Brazil"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S1413-81232024000100206&tlng=pt","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T10:09:53Z","timestamp":1705313393000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1413-81232024000100206&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"alternative-id":["S1413-81232024000100206"],"URL":"https:\/\/doi.org\/10.1590\/1413-81232024291.18142022","relation":{},"ISSN":["1678-4561","1413-8123"],"issn-type":[{"type":"electronic","value":"1678-4561"},{"type":"print","value":"1413-8123"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e18142022"}}